Breaking the Chains of Cholestatic Liver Injury: Advancements and Promising Treatment Strategies
Nov
13
2023
Room 312
-
Hynes Convention Center
4:30
- 6:00 PM EST
Speakers
Description
Basic, clinically translational and human patient studies covering molecular targets and signaling mechanisms aimed to discover new therapeutic avenues for patients with cholestatic liver disease.
Abstracts
- LOSS OF TAZ AFTER YAP DELETION SEVERELY IMPAIRS FOREGUT DEVELOPMENT AND WORSENS CHOLESTATIC HEPATOCELLULAR INJURY
- RUNX1 TRANSCRIPTION FACTOR MEDIATES THE TGFβ-STIMULATED INFLAMMATORY RESPONSE BY CHOLANGIOCYTES IN PRIMARY SCLEROSING CHOLANGITIS
- ELUCIDATING THE MECHANISMS OF KIF12-MEDIATED HIGH GGT CHOLESTASIS
- ESTABLISHMENT OF PFIC 3 MOUSE MODEL CARRYING HUMAN-LIKE BILE ACID COMPOSITION BY IN VIVO LIVER-SPECIFIC GENE DELETION USING ADENO-ASSOCIATED VIRUS AND CRISPR/Cas9 SYSTEM
- SERUM PROTEOMICS REVEALS UNIQUE ASSOCIATION OF CCL24 WITH DISEASE-RELATED PATHWAYS AND SIGNATURES IN PRIMARY SCLEROSING CHOLANGITIS
- EFFECTIVENESS AND SAFETY OF SECOND-LINE THERAPY IN PRIMARY BILIARY CHOLANGITIS (PBC): A PROSPECTIVE MULTICENTER REAL-WORLD COHORT.
Objectives
- Uncover signaling mechanisms involved in inflammatory-driven cholestatic liver injury using animal models.
- Discover potential targets and biomarkers using omic-based studies in patients with cholestatic liver injury.
- Elucidate new therapeutic targets and reevaluate current therapies for cholestatic diseases.